Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib + Fulvestrant vs Chemotherapy in HR+/HER2- Metastatic Breast Cancer
NCT04031885Phase 4Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2019
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 4 trial of abemaciclib in breast cancer, sponsored by Eli Lilly and Company. Started Aug 2019; status: terminated.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04031885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04031885.